| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: SGXP |
| Security Type |
Common Stock |
| Lead Underwriter |
CIBC World Markets Inc Piper Jaffray Cos |
| Days In Registration |
151 |
| Date Filed |
2-Sep-2005 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
SGX Pharmaceuticals Inc, headquartered in San Diego, California, is a biotechnology company focused on the discovery, development, and commercialization of cancer therapeutics. It is developing an internal oncology product pipeline and lead compounds through the application of its proprietary drug discovery platform, Fragments of Active Structures (FAST). The company's pre-clinical development programs include BCR-ABL Kinase Inhibitor Program that focuses on compounds, which inhibit wild-type and Gleevec-resistant mutant forms of BCR-ABL tyrosine kinase, the enzyme that is responsible for CML and MET Tyrosine Kinase Receptor Inhibitor program that inhibits solid tumors. The company was founded in 1998. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
14.2M |
| Contact |
- |
| Number of Employees |
123 |
|
| Original Filing Information |
| US |
| Shares Filed |
4.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
4.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
600.0K |
| File Amount |
$48.0M |
| File Price Range |
$13.00 - $11.00 |
| File Mid Price |
$12.00 |
Current Filing Information
(Amended 25-Jan-2006) |
|
US |
|
Shares Filed |
4.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$30.0M |
| · % Change from Original |
-37.5 |
| File Price Range |
$8.00 - $7.00 |
| File Mid Price |
$7.50 |
|
